List of Excipients in Branded Drug XELSTRYM

XELSTRYM Excipient Strategy and Commercial Opportunities

Last updated: August 5, 2026

XELSTRYM is a dextroamphetamine transdermal system for attention-deficit/hyperactivity disorder in patients aged 6 years and older. Its commercial value depends on controlled transdermal delivery, predictable adhesion, dose flexibility, and reduced reliance on oral administration. The product uses a drug-in-adhesive patch architecture containing acrylic adhesive, polyisobutylene, silicone adhesive, and polyethylene terephthalate components identified in FDA labeling.[1]

The strongest commercial opportunities are improved wear performance, lower skin irritation, manufacturing redundancy, lifecycle products, and platform licensing. Excipient substitution must preserve dextroamphetamine flux, adhesion, release kinetics, stability, and dose proportionality.

What excipients are used in XELSTRYM?

XELSTRYM contains dextroamphetamine in a multilayer transdermal system. FDA labeling identifies acrylic adhesive, polyisobutylene, silicone adhesive, and polyethylene terephthalate among the inactive system components.[1]

Component	Likely system function	Commercial relevance
Acrylic adhesive	Drug-in-adhesive matrix and skin-contact adhesive	Controls drug dispersion, adhesion, release, and manufacturing uniformity
Polyisobutylene	Pressure-sensitive adhesive or adhesive modifier	Supports tack, cohesion, and contact during wear
Silicone adhesive	Skin-contact or adhesive-layer function	Can improve conformability and reduce dependence on acrylic chemistry
Polyethylene terephthalate	Backing or liner material	Provides mechanical strength, barrier properties, and controlled handling
Dextroamphetamine	Active pharmaceutical ingredient	Delivered over the prescribed wear period through the skin

The precise layer assignment and quantitative composition are proprietary formulation information. The public label establishes the composition category but does not disclose the full commercial formulation, excipient grades, supplier identities, or component concentrations.[1]

How does XELSTRYM’s transdermal excipient strategy work?

The formulation strategy combines adhesive performance with transdermal drug delivery. Unlike an oral tablet, XELSTRYM must maintain intimate skin contact for the full wear period while releasing dextroamphetamine at a controlled rate.

Adhesive and drug-release balance

Acrylic and silicone adhesive systems offer different performance profiles. Acrylic systems can provide strong formulation flexibility and drug compatibility. Silicone systems can support skin conformability and relatively low-irritation contact. Polyisobutylene can modify tack, cohesion, and matrix behavior.

The formulation must balance four competing requirements:

1. Sufficient adhesion during routine activity.
2. Controlled dextroamphetamine diffusion.
3. Low residue after removal.
4. Acceptable skin tolerability during repeated use.

Increasing tack can improve wear retention but may increase trauma, residue, or irritation. Increasing permeability can improve delivery but may raise dose variability, skin sensitivity, or systemic exposure.

Skin flux and dose proportionality

XELSTRYM is marketed in four strengths: 4.5 mg, 9 mg, 13.5 mg, and 18 mg.[1] These strengths provide a commercial titration ladder without requiring multiple daily oral doses.

The formulation and patch area, adhesive matrix, drug loading, and permeation behavior must work together to produce predictable systemic exposure. A competing formulation that changes the adhesive polymer or permeation profile would require comparative pharmacokinetic and adhesion evidence.

Wear-time control

The product is designed for a prescribed wear period of up to nine hours.[1] Wear-time flexibility is a commercial differentiator because caregivers can remove the patch to manage late-day exposure, appetite effects, insomnia, or adverse reactions.

This feature creates an excipient opportunity: materials that preserve dose delivery during an intended shorter wear interval while preventing uncontrolled residual delivery after removal. Any such strategy would need to be evaluated through in vitro release, adhesion, residual drug, skin permeation, and clinical pharmacokinetic studies.

What formulation attributes create commercial opportunities for XELSTRYM?

The most actionable opportunities involve performance improvements rather than adding new pharmacologic activity.

Improved adhesion in pediatric use

Children may sweat, exercise, swim, or repeatedly contact the patch. Adhesive suppliers can compete by offering:

• Higher humidity resistance.
• Better adhesion during movement.
• Lower edge lift.
• Reduced adhesive residue.
• Improved adhesion after application to variable skin types.
• Lower irritation after repeated daily use.

An improved adhesive system could support a supplemental approval if the change materially affects product performance. A material change may also require bridging studies and updated manufacturing controls.

Reduced skin irritation

Repeated transdermal administration creates a predictable lifecycle opportunity. Skin reactions can result from the active drug, adhesive polymer, residual monomers, tackifiers, solvents, backing materials, or occlusion.

Potential development programs include:

• Low-irritation acrylic systems.
• Silicone-dominant skin-contact layers.
• Hypoallergenic liner and backing materials.
• Lower-residue formulations.
• Adhesive systems with reduced extractables and leachables.
• Patch designs that reduce occlusion.

A reduced-irritation formulation would have commercial value in patients who discontinue transdermal treatment because of erythema, pruritus, or discomfort.

Better removal characteristics

Removal performance is clinically relevant for a pediatric patch. Excessive peel force can cause pain or skin stripping. Insufficient peel force can cause premature detachment.

Excipient and component suppliers can differentiate through peel-force control, residue reduction, and predictable performance across temperature and humidity conditions. A formulation with reliable removal could support adherence and caregiver acceptance even if the active drug remains unchanged.

Heat and water resistance

Transdermal systems can experience performance changes under heat. Heat may increase drug diffusion, adhesive flow, skin permeability, or systemic exposure. Water exposure can weaken adhesion or alter the patch edge.

Commercially relevant development targets include:

• Stable drug flux under elevated temperature.
• Improved adhesion after bathing or sweating.
• Reduced adhesive cold flow.
• Better packaging protection against humidity.
• Defined performance after short-term temperature excursions.

These attributes are particularly relevant for pediatric use and markets with high ambient temperatures.

What patents protect XELSTRYM’s excipient and delivery technology?

XELSTRYM’s commercial protection is likely to depend primarily on transdermal formulation, delivery-system, manufacturing, and method-of-use claims rather than on ownership of the individual excipients.

Acrylic adhesive, silicone adhesive, polyisobutylene, and polyethylene terephthalate are established materials. They generally do not create a durable product monopoly by themselves. Patent value is more likely to arise from combinations such as:

• Specific dextroamphetamine loading ranges.
• Defined adhesive-polymer ratios.
• Transdermal flux windows.
• Patch dimensions and layer architecture.
• Release profiles over the wear period.
• Reduced skin irritation or improved adhesion.
• Methods for treating ADHD with a dextroamphetamine patch.
• Manufacturing processes that provide content uniformity and stability.

The FDA-approved label should be read together with current Orange Book listings and publicly available patent records when assessing the enforceable estate.[2] FDA labeling alone does not establish the complete scope, expiration dates, terminal disclaimers, patent-term adjustments, or litigation position of the product’s intellectual-property portfolio.

Are the excipients themselves a strong barrier to generic entry?

Usually, no. A generic or 505(b)(2) applicant may be able to use the same excipients, alternative grades, or functionally equivalent materials, subject to FDA requirements.

The stronger barriers are technical:

• Reproducing drug distribution in the adhesive matrix.
• Matching transdermal delivery and systemic exposure.
• Demonstrating adhesion across the labeled wear period.
• Controlling residual drug after removal.
• Matching the product’s strength and dose-titration structure.
• Establishing adequate stability for the finished patch.
• Scaling coating, drying, slitting, converting, and pouching operations.

These barriers can delay competition even where the individual excipients are widely available.

When does XELSTRYM lose exclusivity?

XELSTRYM’s exclusivity profile has several separate components:

Protection type	Relevance to XELSTRYM
FDA regulatory exclusivity	May apply based on the approval pathway and clinical investigation supporting the product
Orange Book patents	May cover formulation, delivery system, manufacturing, or method of use
Trade secrets	May cover formulation ratios, coating conditions, process controls, and supplier specifications
Trademark protection	Protects the XELSTRYM brand but does not prevent approval of a generic equivalent
Controlled-substance regulation	Creates distribution and compliance requirements but is not patent exclusivity

Dextroamphetamine is an established active ingredient, so XELSTRYM does not receive the same new-molecular-entity exclusivity profile as a novel active substance. The principal regulatory and patent questions concern the transdermal dosage form and the scope of listed patents.[2]

A generic applicant could challenge relevant Orange Book patents through a Paragraph IV certification. A Paragraph IV filing would create potential patent litigation and could trigger the statutory 30-month stay if the NDA holder or patent owner filed suit within the applicable period.[3]

What Paragraph IV and generic entry risks exist for XELSTRYM?

XELSTRYM faces a more complex generic pathway than an immediate-release tablet because transdermal products require product-specific performance evidence.

A generic applicant would likely focus on:

• Same active ingredient and dosage form.
• Equivalent strengths.
• Comparable adhesive performance.
• Comparable delivery rate and exposure.
• Skin irritation and sensitization.
• Residual drug and removal characteristics.
• Stability of the patch and pouch.
• Design-around options for formulation or layer construction.

Potential entry scenarios include:

Same-formulation generic

A competitor could attempt to match the listed formulation closely. This approach may simplify development but increases exposure to formulation and delivery patents.

Design-around transdermal system

A competitor could use a different adhesive polymer, patch area, backing layer, or drug-matrix architecture. This may reduce patent exposure but increase development and regulatory risk.

505(b)(2) alternative

A company could pursue a modified transdermal dextroamphetamine product with different wear time, adhesion, dosing, or delivery characteristics. This route may offer a differentiated commercial profile but would not necessarily receive the same substitution treatment as an ANDA-approved generic.

Authorized generic

The NDA holder or a commercialization partner could launch an authorized generic to control price erosion after patent expiry or to respond to an early competitive launch.

How does XELSTRYM compare with Daytrana and oral ADHD products?

XELSTRYM competes against both other patches and established oral stimulants.

Product category	Active ingredient	Delivery	Main commercial advantage	Main limitation
XELSTRYM	Dextroamphetamine	Transdermal	Flexible wear time and non-oral administration	Adhesion, skin reactions, and patch visibility
Daytrana	Methylphenidate	Transdermal	Established patch category and flexible wear	Methylphenidate pharmacology differs from amphetamine
Oral amphetamine products	Amphetamine salts or lisdexamfetamine	Oral	Broad generic availability and established prescribing	Swallowing, daily dosing, and adherence issues
Oral methylphenidate products	Methylphenidate	Oral	Large range of immediate- and extended-release options	Oral administration and duration constraints

XELSTRYM’s commercial differentiation is not based solely on the active ingredient. It combines dextroamphetamine pharmacology with a non-oral delivery route and removal-based exposure control.

What licensing and manufacturing opportunities exist around XELSTRYM?

The most credible licensing opportunities are platform-oriented.

Excipient and adhesive licensing

Material suppliers can license:

• Pediatric-compatible acrylic adhesives.
• Silicone pressure-sensitive adhesives.
• Polyisobutylene systems with controlled tack.
• Low-extractable backing and liner materials.
• Adhesive systems with improved heat and humidity performance.

The value proposition must include validated manufacturing performance, not only a new excipient identity.

Contract manufacturing

Transdermal manufacturing requires specialized capabilities:

• Precision coating.
• Controlled drying.
• Lamination.
• Slitting and die-cutting.
• In-process content uniformity testing.
• Pouch sealing.
• Visual inspection and defect detection.
• Stability testing under temperature and humidity stress.

A contract manufacturer with redundant coating and converting capacity can reduce supply-chain risk for XELSTRYM or a competing product.

Regional supply opportunities

Commercial partners may target regional supply of:

• Pharmaceutical-grade adhesive polymers.
• PET backing and release liners.
• Unit-dose pouches.
• Coated laminate.
• Printing and serialization components.
• Specialized equipment for transdermal patch production.

The main qualification burden is consistency across lots. Changes in polymer molecular weight, residual solvent, tackifier content, or surface treatment can affect drug release and adhesion.

What FDA regulatory issues affect excipient changes?

FDA evaluation of a changed transdermal product would depend on the effect of the change, not simply on whether the excipient is listed in the FDA Inactive Ingredient Database.

Relevant regulatory issues include:

• Excipient safety and route-specific precedent.
• Drug-excipient compatibility.
• Adhesion and wear testing.
• In vitro release and permeation.
• Comparative pharmacokinetics.
• Skin irritation and sensitization.
• Extractables and leachables.
• Container-closure integrity.
• Microbial and particulate controls.
• Stability after manufacturing scale-up.

The Inactive Ingredient Database can support regulatory precedent, but it does not replace product-specific evidence for a complex transdermal system.[4] FDA guidance for transdermal and topical delivery systems emphasizes characterization of adhesion, drug release, permeation, dose delivery, and product quality.[5]

What is the commercial value of an improved XELSTRYM excipient system?

An improved system could create value in five ways:

1. Increase persistence by reducing premature patch detachment.
2. Expand use among patients with adhesive-related skin reactions.
3. Improve caregiver acceptance through easier removal and lower residue.
4. Reduce manufacturing waste and batch failures.
5. Support a lifecycle supplement or differentiated 505(b)(2) product.

The most attractive target is a formulation that improves adhesion and skin tolerability without materially changing dextroamphetamine exposure. A change that alters delivery kinetics may create a stronger product distinction but will require a more extensive clinical and regulatory package.

Key Takeaways

• XELSTRYM uses a dextroamphetamine transdermal system containing acrylic adhesive, polyisobutylene, silicone adhesive, and polyethylene terephthalate components identified by FDA labeling.
• The principal commercial moat is the integrated drug-in-adhesive delivery system, not ownership of common excipients.
• High-value formulation opportunities include lower irritation, better adhesion, lower residue, improved heat resistance, and stronger performance during sweating or water exposure.
• Generic competition must match transdermal delivery, adhesion, skin tolerability, stability, and dose performance.
• Paragraph IV risk will depend on the current Orange Book patent listings and the scope of formulation, delivery-system, manufacturing, and method-of-use claims.
• The best licensing targets are specialized adhesive systems, transdermal manufacturing capacity, and validated component supply.
• XELSTRYM is a small-molecule product, so biosimilar risk does not apply. Its competitive risk is generic, 505(b)(2), authorized-generic, and competing ADHD product entry.

FAQs About XELSTRYM Excipient Strategy

Can XELSTRYM use a different adhesive and remain therapeutically equivalent?

Potentially, but the sponsor would need to demonstrate that the changed adhesive does not materially alter drug release, skin permeation, adhesion, irritation, stability, or systemic exposure.

Are silicone adhesives safer than acrylic adhesives for XELSTRYM?

Neither class is universally safer. Safety depends on the specific polymer, additives, residual solvents, drug compatibility, contact time, and patient skin response.

Can a generic XELSTRYM use different backing and liner materials?

Yes, subject to regulatory requirements. The alternative materials must support equivalent product quality, protection, handling, adhesion, and delivery performance.

Is XELSTRYM protected by biologic or biosimilar exclusivity?

No. XELSTRYM contains the small-molecule active ingredient dextroamphetamine. Competition would proceed through generic or alternative small-molecule pathways rather than biosimilar approval.

What is the most valuable excipient innovation for XELSTRYM?

A low-irritation adhesive system that maintains reliable nine-hour wear, resists heat and moisture, leaves minimal residue, and preserves dextroamphetamine delivery would have the strongest commercial potential.

References

1. U.S. Food and Drug Administration. (2022). XELSTRYM (dextroamphetamine) transdermal system prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
3. U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions: Refuse-to-receive standards.
4. U.S. Food and Drug Administration. (2024). Inactive ingredient database.
5. U.S. Food and Drug Administration. (2020). Transdermal and topical delivery systems: Product development and quality considerations.